2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林召开，作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学专家参与，为全球学者提供了良好的交流平台。日前，ESMO已公布大会常规摘要（含Oral、Mini Oral、Poster三类）和“突破性摘要”（Late-Breaking Abstract，LBA）标题。肿瘤瞭望特将目前乳腺癌领域入选的中国专家投稿壁报研究进行汇总，并诚邀您持续关注重磅研究进展！
编者按：2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林召开，作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学专家参与，为全球学者提供了良好的交流平台。日前，ESMO已公布大会常规摘要（含Oral、Mini Oral、Poster三类）和“突破性摘要”（Late-Breaking Abstract，LBA）标题。肿瘤瞭望特将目前乳腺癌领域入选的中国专家投稿壁报研究进行汇总，并诚邀您持续关注重磅研究进展！
Breast cancer，early stage
（早期乳腺癌）
298P-Development and validation of a novel HER2RI assay for predicting the risk of recurrence and survival in Asian population with HER2-positive breast cancer
用于预测亚洲HER2阳性乳腺癌患者复发和生存风险的新型HER2RI检测方法的开发和验证
讲者：Yi-Kun Kang(Beijing，China)
300P-TIME-HER:A Dynamic Predictive Model for Prognosis of HER2-Positive Early Breast Cancer after HER2-targeted Therapy
TIME-HER：HER2靶向治疗后HER2阳性早期乳腺癌预后的动态预测模型
讲者：Qingyao Shang(Beijing，China)
305P-Neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer:three-year outcomes from the MUKDEN 01 study
MUKDEN 01研究三年随访结果：吡咯替尼联合来曲唑及达尔西利新辅助治疗三阳性乳腺癌的疗效分析
讲者：刘彩刚（中国医学大学附属盛京医院）
306P-Neoadjuvant SHR-A1811 with or without pyrotinib in HER2-positive breast cancer(MUKDEN 07):A multi-cohort，multicenter，phase II clinical trial
MUKDEN 07研究：一项针对HER2阳性乳腺癌的多队列、多中心Ⅱ期临床试验，评估新辅助治疗中SHR-A1811联合或不联合吡咯替尼的疗效
讲者：刘彩刚（中国医学大学附属盛京医院）
312P-Comparison of survival outcomes between neoadjuvant and adjuvant therapy in patients with T1c，lymph node-negative，and hormone receptor-negative breast cancer:a study based on the SEER database and a Chinese cohort
T1c期、淋巴结阴性且激素受体阴性乳腺癌患者新辅助治疗与辅助治疗生存结局的对比研究：基于SEER数据库与中国队列的分析
讲者：Shiyu Liang(Chengdu，China)
317P-Myeloprotection with Trilaciclib in Hormone Receptor(HR)-Negative early breast cancer receiving adjuvant therapy
Trilaciclib在激素受体（HR）阴性早期乳腺癌辅助治疗中的骨髓保护作用
讲者：Jiajia Huang(Guangzhou，China)
344P-Inadequate ovarian suppression in young premenopausal women with estrogen receptor-positive breast cancer on ovarian suppression therapy
接受卵巢功能抑制治疗的年轻绝经前雌激素受体阳性乳腺癌患者卵巢抑制不充分的现象
讲者：Dar-Ren Chen(Changhua City，Taiwan)
348P-Ten-Year Outcomes of Epirubicin Plus Paclitaxel Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel in Hormone Receptor–Positive，ERBB2-Negative，Node-Positive Breast Cancer:A Phase 3 Randomized Clinical Trial
表柔比星联合紫杉醇对比表柔比星联合环磷酰胺序贯紫杉醇治疗激素受体阳性、ERBB2阴性、淋巴结阳性乳腺癌的10年随访结局比较：一项3期随机临床试验
讲者：Liuliu Quan(Beijing，China)
382P-A modern DCIS-IBC guide board for postoperative upgrading in ductal carcinoma in situ
导管原位癌术后升级为浸润性乳腺癌的现代风险评估指南框架
讲者：Chenglong Duan(xian，China)
383P-Spatial transcriptomics reveals biological disparities in ipsilateral breast tumor recurrence after breast-conserving surgery
空间转录组学揭示保乳术后同侧乳腺肿瘤复发的生物学差异
讲者：FEILIN QU(Shanghai，China)
385P-Is axillary intervention necessary for selected patients with cN0-1 breast cancer after neoadjuvant chemotherapy?
新辅助化疗后的cN0-1乳腺癌患者是否有必要进行腋窝干预？
讲者：Yuhan Zhang(Xi’an，Shaanxi Province，China)
386P-The Innovative Lancet Technique for Breast-Conserving Oncoplastic Surgery in Small-to Medium-Sized Breasts with Tumors in the Lower Inner Quadrant:A Multicenter Retrospective Study(IOS Study)
针对中小乳房下内侧象限肿瘤的保乳整形手术创新Lancet技术：一项多中心回顾性研究（IOS研究）
讲者：Wenjie Shi(Magdeburg，Germany)
389P-A Competing Risk Analysis Model to Explore the Impact of Postoperative Radiotherapy for Sentinel Lymph Node Micrometastases or ITCs in Female Breast Cancer
竞争风险分析模型探讨术后放疗对女性乳腺癌前哨淋巴结微转移或孤立肿瘤细胞（ITCs）的影响
讲者：Yudong Zhou(xian，China)
391P-Application of Preoperative 3-dimensional Vascular Reconstruction Assessment in Preventing Ischemic Complications After Nipple-Sparing Mastectomy:A Randomized Controlled Trial
术前三维血管重建评估在预防保留乳头乳房切除术后缺血性并发症中的应用：一项随机对照试验
讲者：Xiaoqi Zhang(Guangzhou，China)
398P-Patient-reported outcomes(PROs)with GnRHa as ovarian function suppression(OFS)treatment in pre-menopausal Chinese patients with hormone receptor-positive(HR+)early breast cancer(EBC):a real-world observational investigation
GnRHa作为卵巢功能抑制（OFS）治疗绝经前激素受体阳性（HR+）早期乳腺癌（EBC）患者的患者报告结局（PROs）：一项真实世界观察性研究
讲者：范蕾（复旦大学附属肿瘤医院）
403P-Axillary Lymph Node Dissection Offers No Survival Benefit in Breast Cancer Patients with Sentinel Lymph Node Micrometastases After Neoadjuvant Therapy
腋窝淋巴结清扫术对新辅助治疗后前哨淋巴结微转移的乳腺癌患者无生存获益
讲者：Jianing Zhang(Xi’an，China)
414P-Prognostic Value of ER reduction rate between pre-and post-Neoadjuvant Chemotherapy in Patients with ER-Positive/HER2-Negative Breast Cancer
新辅助化疗前后ER降低率对ER阳性/her2阴性乳腺癌患者的预后价值
讲者：Shunyi Liu(Fuzhou，China)
416P-Diverse adjuvant treatment in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy:A single center real-world study
新辅助化疗后残留病灶的三阴性乳腺癌患者的多样化辅助治疗：一项单中心真实世界研究
讲者：Xi Chen(Beijing，China)
417P-Proteomic analysis of residual disease identifies potential prognostic biomarkers of triple-negative breast cancer after neoadjuvant chemotherapy
三阴性乳腺癌新辅助化疗后残留病灶的蛋白质组学分析确定潜在的预后生物标志物
讲者：Xi Chen(Beijing，China)
418P-Impact of BRCAness Status on Prognosis and Chemotherapy Sensitivity in Non-pCR Triple-Negative Breast Cancer Patients After Neoadjuvant Treatment
BRCA样状态对新辅助治疗后未达病理完全缓解（non-pCR）三阴性乳腺癌患者预后及化疗敏感性的影响
讲者：Hangcheng Xu(Beijing，China)
Breast cancer，locally advanced
（局部晚期乳腺癌）
466P-Efficacy and Safety of JS105，a Selective Inhibitor of Mutant PI3Kα，in Patients with Advanced Cancer
选择性突变型PI3Kα抑制剂JS105在晚期癌症患者中的疗效与安全性研究
讲者：闫敏（河南省肿瘤医院）
468P-The Clinical Significance and Prognostic Impact of stromal tumor infiltrating lymphocytes in HER2-Positive Breast Cancer:Including a Neoadjuvant Subgroup Analysis
HER2阳性乳腺癌间质肿瘤浸润淋巴细胞的临床意义和预后影响：包括新辅助治疗亚组分析
讲者：Yujing Chang(Chengdu，China)
470P-Neoadjuvant cadonilimab(anti-PD-1/CTLA-4 bispecific antibody)plus chemotherapy in early or locally advanced triple-negative breast cancer:supplementary biomarker analyses from CABIN trial
新辅助cadonilimab（抗pd-1/CTLA-4双特异性抗体）联合化疗治疗早期或局部晚期三阴性乳腺癌：来自CABIN试验的补充生物标志物分析
讲者：TAO WU(Changde City，China)
472P-The mechanism and preclinical translational research of targeted inhibition of ATM enhancing the therapeutic efficacy of PD-1/PD-L1 inhibitors in triple-negative breast cancer by modulating CD8?T cells in the tumor immune microenvironment
靶向抑制ATM通过调控肿瘤免疫微环境中CD8?T细胞增强PD-1/PD-L1抑制剂治疗三阴性乳腺癌的机制及临床前转化研究
讲者：Xiaojing Guo(Tianjin，China)
473P-Neoadjuvant Trilaciclib plus chemotherapy and anti-PD1-antibody for locally advanced triple-negative breast cancer:Preliminary short-term efficacy and safety results from a single-arm，multicenter，phase II trial
新辅助治疗中Trilaciclib联合化疗及抗PD-1抗体治疗局部晚期三阴性乳腺癌：一项单臂、多中心Ⅱ期试验的初步短期疗效与安全性结果
讲者：Jiaxuan Liu(Beijing，China)
479P-H4K8la/CXCL10-driven M2 polarization via tumor cell-macrophage lactate feedback loop mediates doxorubicin resistance in TNBC
H4K8la/CXCL10通过肿瘤细胞-巨噬细胞乳酸反馈回路驱动M2型巨噬细胞极化，介导三阴性乳腺癌对多柔比星的耐药性
讲者：Qingqing Wang(Wuhan，China)
Breast cancer，metastatic
（转移性乳腺癌）
490P-Bireociclib plus Letrozole/Anastrozole versus Placebo plus Letrozole/Anastrozole for the Treatment of HR+/HER2-Advanced Breast Cancer:Interim Analysis of BRIGHT-3 study
吡洛西利联合来曲唑/阿那曲唑vs安慰剂联合来曲唑/阿那曲唑治疗HR+/HER2-晚期乳腺癌的比较：BRIGHT-3研究的期中分析
讲者：张清媛（哈尔滨医科大学附属肿瘤医院）
495P-Safety and efficacy of nab-Sirolimus(HB1901)+endocrine therapy in HR+/HER2-advanced breast cancer after standard therapy failure:A multicenter，open-label，phase 2 study
白蛋白结合型西罗莫司（HB1901）联合内分泌治疗在标准治疗失败后的HR+/HER2-晚期乳腺癌中的安全性和有效性：一项多中心、开放标签、II期研究
讲者：马飞（中国医学科学院肿瘤医院）
501P-Efficacy and Safety Outcomes across Young to Older Age Groups of Patients with HR+/HER2-Advanced Breast Cancer Treated with Bireociclib plus Endocrine Therapy:a Pooled Analysis of BRIGHT Studies
吡洛西利联合内分泌治疗HR+/HER2-晚期乳腺癌年轻和老年患者的疗效和安全性结局：BRIGHT研究的汇总分析
讲者：张清媛（哈尔滨医科大学附属肿瘤医院）
505P-Safety and Preliminary Efficacy of a Novel CDK2/4 Inhibitor TYK-00540 in Patients with Advanced Solid Tumors:Results from a Phase I Dose-Escalation Study
新型CDK2/4抑制剂TYK-00540用于晚期实体瘤患者的安全性和初步疗效：来自1期剂量递增研究的结果
讲者：孟艳春（复旦大学附属肿瘤医院）
509P-A Phase II Trial of Anlotinib and Fulvestrant in Patients with HR-Positive and HER2-Negative，Secondary Hormone Resistant，Metastatic Breast Cancer
安罗替尼+氟维司群治疗HR+/HER2-继发性激素抵抗性转移性乳腺癌患者的2期试验
讲者：王晓稼（浙江省肿瘤医院）
513P-TY-302，a CDK4/6 inhibitor(CDK4/6i)，combined with toremifene in patients with advanced solid tumors:Results from a phase Ia/Ib study.
CDK4/6抑制剂（CDK4/6i）TY-302联合托瑞米芬治疗晚期实体瘤：Ia/Ib期研究结果
讲者：马飞（中国医学科学院肿瘤医院）
518P-Efficacy and Safety of Treatments in HR+HER2-Advanced Breast Cancer After Cyclin-Dependent Kinase 4/6 inhibitors progression:A Network Meta-Analysis and Scoping Review
CDK4/6抑制剂治疗进展后HR+/HER2-晚期乳腺癌治疗的疗效和安全性：一项网状meta分析和范围综述
讲者：佟仲生（天津医科大学肿瘤医院）
525P-Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive，HER2-Negative Advanced Breast Cancer:A Network Meta-Analysis of Randomized Controlled Trials
CDK4/6抑制剂后治疗方案对HR+/HER2阴-晚期乳腺癌的疗效和安全性：一项随机对照试验的网络荟萃分析
讲者：Junxiao Wang(Fuzhou，China)
529P-PIK3CA Mutation Profiles in Primary and Metastatic Lesions in Chinese Patients with Hormone Receptor-Positive，HER2-Negative Breast Cancer
中国激素受体阳性、HER2阴性乳腺癌患者原发性和转移性病灶中PIK3CA的突变谱
讲者：徐贵颖（吉林省肿瘤医院）
538P-Preliminary efficacy and safety of TQB2102 in patients with HER2 positive Recurrent/Metastatic Breast Cancer:Results from a phase Ib study
TQB2102治疗HER2阳性复发/转移性乳腺癌患者的初步疗效和安全性：一项Ib期研究的结果
讲者：张清媛（哈尔滨医科大学附属肿瘤医院）
545P-A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined with Chemotherapy(IPyC)for HER2+Metastatic Breast Cancer
伊尼妥单抗+吡咯替尼联合化疗（IPyC）治疗HER2+转移性乳腺癌的疗效和安全性回顾性多中心队列研究
讲者：Wu Fan(Fuzhou，China)
546P-Efficacy and safety of Pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer:a multicenter，retrospective，real-world study
既往曲妥珠单抗和帕妥珠单抗治疗HER2阳性转移性乳腺癌后，接受以吡咯替尼为基础的治疗的有效性和安全性：一项多中心、回顾性、真实世界研究
讲者：王涛（解放军总医院第五医学中心）
549P-Phase I study of ARX788 plus toripalimab in advanced solid tumors with expansion in HER2-low advanced breast cancer.
ARX788联合特瑞普利单抗治疗HER2低表达的晚期实体瘤的I期研究
讲者：王晓稼（浙江省肿瘤医院）
551P-SHR-A1811 combined with Adebrelimab in HR-/HR-low，HER2-low metastatic breast cancer:Preliminary results from an open-label，single-arm，phase II Trial
SHR-A1811联合阿得贝利单抗治疗HR-/HR低表达、HER2低表达的转移性乳腺癌：开放标签、单臂、II期试验的初步结果
讲者：Jiaxuan Liu(Beijing，China)
552P-Phase I study data of a novel eribulin-based HER2 ADC:Safety and efficacy of SMP-656 in HER2-expressing solid tumor
基于艾立布林的新型HER2 ADC的I期研究数据：SMP-656在HER2表达实体瘤中的安全性和疗效
讲者：张剑（复旦大学附属肿瘤医院）
556P-Updated Efficacy of Anti-TROP2 ADC ESG401 for First-Line Metastatic TNBC
抗TROP2 ADC ESG401治疗一线转移性TNBC的最新疗效
讲者：邱福铭（浙江大学医学院附属第二医院）
559P-SHR-A1921，a novel trophoblast cell-surface antigen 2 targeted antibody-drug conjugate，with or without adebrelimab in advanced triple-negative breast cancer(TNBC):data from two open-label，multicenter clinical trials
SHR-A1921，一种新型靶向滋养层细胞表面抗原2的抗体药物偶联物，联合或不联合阿得贝利单抗（adebrelimab）治疗晚期三阴性乳腺癌（TNBC）：两项开放标签、多中心临床试验的数据
讲者：史业辉（天津医科大学肿瘤医院）
564P-Combined PD-1 Inhibition and Chidamide in Metastatic Triple-Negative Breast Cancer:A Phase II Clinical Trial
PD-1抑制联合西达本胺治疗转移性三阴性乳腺癌：一项II期临床试验
讲者：Sifen Wang(Guangzhou，China)
571P-Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis:A Phase II Study
阿得贝利单抗联合阿帕替尼和依托泊苷治疗HER2阴性乳腺癌脑转移：一项II期研究
讲者：王涛（解放军总医院第五医学中心）
581P-Improving Survival in Heavily Treated Metastatic Breast Cancer Through Personalized Chemotherapy Selection Using Ex Vivo Expanded Circulating Tumor Cells
通过使用体外扩增的循环肿瘤细胞进行个体化化疗选择来改善重度治疗的转移性乳腺癌患者的生存
讲者：Wen-Ying Lin(Taipei City，Taiwan)
595P-Efficacy and Safety of Rivaroxaban Prophylaxis on Catheter-Related Thrombosis in Breast Cancer Patients Undergoing Chemotherapy with PICC:A Prospective Cohort Study
利伐沙班预防乳腺癌化疗患者PICC导管相关性血栓形成的有效性和安全性：一项前瞻性队列研究
讲者：Die Sang(Beijing，China)
598P-An observational clinical study to evaluate the consistency of PIK3CA mutations in tumor tissues and corresponding plasma circulating tumor DNA(ctDNA)of patients with HR+mBC
一项观察性临床研究，旨在评估HR+mBC患者肿瘤组织中PIK3CA突变和相应血浆循环肿瘤DNA（ctDNA）的一致性
讲者：欧阳取长（湖南省肿瘤医院）
599P-Efficacy and Safety of Dalpiciclib Combined with Endocrine Therapy After Progression on Prior CDK4/6 Inhibitors in HR+/HER2-Advanced Breast Cancer
在既往CDK4/6抑制剂经治的HR+/HER2-晚期乳腺癌发生进展后，达尔西利联合内分泌治疗的疗效和安全性
讲者：李俏（中国医学科学院肿瘤医院）
600P-Matching-Adjusted Indirect Comparison of Bireociclib Plus Fulvestrant versus Dalpiciclib Plus Fulvestrant as Second-Line Treatment of HR+/HER2-Advanced Breast Cancer(ABC)
通过匹配校正间接比较吡洛西利+氟维司群与达尔西利+氟维司群作为HR+/HER2-晚期乳腺癌二线治疗的疗效（ABC）
讲者：王佳玉（中国医学科学院肿瘤医院）
602P-VMP1 inhibits the progression of breast cancer via regulating PI3K/AKT and MEK/ERK signaling pathway
VMP1通过调控PI3K/AKT和MEK/ERK信号通路抑制乳腺癌的进展
讲者：Shuzhao Chen(Guangzhou，China)
609P-Real-world Application of 18F-FES PET/CT on HR+Breast Cancer Patients with Brain Metastases
18F-FES PET/CT在HR+乳腺癌脑转移患者中的实际应用
讲者：王碧芸（复旦大学附属肿瘤医院）
612P-Impact of Rivaroxaban on Prophylaxis Against Catheter-Related Thrombosis in Breast Cancer Patients:A cohort study
利伐沙班对预防乳腺癌患者导管相关血栓形成的影响：一项队列研究
讲者：Yurong Zhang(Beijing，China)
625TiP-A Multicenter，Prospective，Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Trop-2 ADC联合治疗晚期三阴性乳腺癌的多中心、前瞻性、队列研究
讲者：郝春芳（天津医科大学肿瘤医院）
631eP-Real-world study on the efficacy and safety of Dalpiciclib in elderly patients with HR-positive，HER2-negative advanced breast cancer in the Xinjiang region
新疆地区老年HR+/HER2-晚期乳腺癌患者应用达尔西利疗效及安全性的真实世界研究
讲者：Yan Li(Urumqi，China)
635eP-The necessity of adding anti-HER2 antibody to TKI in trastuzumab-resistant，HER2-positive ABC:a multicenter real-world study
曲妥珠单抗耐药的HER2阳性ABC患者中，TKI联合抗HER2抗体的必要性：一项多中心真实世界研究
讲者：Ruixia Song(Beijing，China)
636eP-Real-world efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer:Evidence from a Chinese population
T-DXd在HER2阳性和HER2低表达转移性乳腺癌中的真实疗效和安全性：来自中国人群的证据
讲者：张剑（复旦大学附属肿瘤医院）
637eP-Clinical Outcomes and Safety of Sacituzumab Govetican in Chinese Metastatic HER2 Negative Breast Cancer Patients:A Real World Study
SG治疗中国转移性HER2阴性乳腺癌患者的临床结局和安全性：一项真实世界研究
讲者：Yuxin Mu(Shanghai，China)
638eP-Construction of an Efficacy Prediction Model for T-DXd Treatment of HER2-Positive and HER2-Negative Breast Cancer Based on Hematological Indicators:A Multicenter Real-World Study
基于血液学指标构建T-DXd治疗HER2阳性和HER2阴性乳腺癌疗效预测模型：一项多中心真实世界研究
讲者：Yanfang Su(Beijing，China)
647eP-Efficacy and safety profiles of PARP inhibitors in Chinese patients with metastatic breast cancer:a multi-center real-world study
PARP抑制剂治疗中国转移性乳腺癌患者的疗效和安全性：一项多中心真实世界研究
讲者：Xuenan Peng(Beijing，China)
648eP-Analysis of efficacy and safety of eribulin in the treatment of advanced breast cancer in the real-world
艾立布林治疗晚期乳腺癌的真实世界疗效和安全性分析
讲者：Xiao Chen(Shenzhen，China)
652eTiP-A Phase 1b/2 study of FWD1802，a novel oral estrogen receptor(ER)degrader(SERD)，in combination with multiple CDK4/6 inhibitors(CDK4/6i)and mTOR inhibitor in ER+/HER2-advanced or metastatic breast cancer(a/m BC)
FWD1802（一种新型口服ER降解剂）联合多种CDK4/6抑制剂（CDK4/6i）和mTOR抑制剂治疗ER+/HER2-晚期或转移性乳腺癌（A/m BC）的1b/2期研究
讲者：孟艳春（复旦大学附属肿瘤医院）
653eTiP-Translational study and First-in-Human(FIH)study design of KH815，a novel dual-payload TROP-2 targeted Antibody-Drug Conjugate(ADC)，in patients with advanced solid tumors
KH815是一种新型双有效载荷靶向TROP-2的抗体-药物偶联物（ADC），用于晚期实体瘤患者的转化研究和首次入人（FIH）研究设计
讲者：马飞（中国医学科学院肿瘤医院）
京公网安备 11010502033352号